Monday, July 15, 2024
HomeNewsViz.AI And Avincenna.AI Have Partnered To Launch Artificial Intelligence-Powered Care Solution For...

Viz.AI And Avincenna.AI Have Partnered To Launch Artificial Intelligence-Powered Care Solution For Aortic Disease has recently partnered with to launch its artificial intelligence-powered smart care solution for patients suffering from fatal pulmonary embolism and aortic disease. The new platform would assist patients in making better decisions regarding the treatment of such fatal diseases. 

Both the companies plan to integrate’s algorithm for pulmonary embolism and different types of aortic diseases with’s intelligence care coordination system to develop a wholesome solution for all kinds of patient needs. 

Dr. Richard Saxon, a radiologist at Tri-City Medical center, said, “The addition of artificial intelligence-powered workflows will decrease the time from diagnosis to treatment and help to coordinate care for patients suffering from life-threatening pulmonary embolism and aortic disease. It will also help to facilitate faster and easier treatment decisions across health systems, and should improve outcomes for patients.”

Read More: AWS Launched Its First Public Sector Startup Ramp In India is a San Francisco-based company founded in 2016. It is a leading provider of artificial intelligence-driven healthcare software that helps patients and doctors effectively treat several diseases. Many global leaders have invested in, like Google Ventures, Kleiner Perkins, Greenoaks, and Innovation Endeavors. 

CEO and co-founder of, Chris Mansi, said, “We are delighted to partner with to bring intelligent care coordination to the peripheral vascular and vascular fields. This will form part of a broader Viz platform, where any patient with a life-threatening disease can benefit from artificial intelligence-powered triage, fast mobile communication, and synchronized care coordination.” 

He further mentioned that this partnership of the two companies would help innumerable patients avail advantage of artificial intelligence and help hospitals generate better clinical results. 
Cyril Di Grandi founded in 2018. The startup specializes in artificial intelligence-powered imaging solutions for radiology applications. Earlier, the company received approval from the Food and Drug Administration for its solution for neurovascular emergencies.

Subscribe to our newsletter

Subscribe and never miss out on such trending AI-related articles.

We will never sell your data

Join our WhatsApp Channel and Discord Server to be a part of an engaging community.

Dipayan Mitra
Dipayan Mitra
Dipayan is a news savvy writer, who does not leave a single page of news paper unturned. He is also a professional vocalist who enjoys ghazals. Building a dog shelter is his forever dream.


Please enter your comment!
Please enter your name here

Most Popular